Yoshito Hayashi1, Tsutomu Nishida2, Shusaku Tsutsui3, Takashi Ohta4, Shinjiro Yamaguchi4, Masayoshi Horimoto5, Eiji Masuda6, Hiroyuki Narahara7, Aya Sugimoto2, Yoshiki Tsujii1, Kunio Suzuki5, Hideki Hagiwara4, Hideki Iijima1, Tetsuo Takehara8. 1. Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, 565-0871, Osaka, Japan. 2. Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan. 3. Department of Gastroenterology, Itami City Hospital, Itami, Japan. 4. Department of Gastroenterology, Kansai Rosai Hospital, Amagasaki, Japan. 5. Department of Gastroenterology, Saiseikai Senri Hospital, Suita, Japan. 6. Department of Gastroenterology, National Hospital Organization Osaka Minami National Hospital, Kawachinagano, Japan. 7. Department of Gastroenterology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan. 8. Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, 565-0871, Osaka, Japan. takehara@gh.med.osaka-u.ac.jp.
Abstract
BACKGROUND: Gastric cancer is one of the leading causes of malignant disease-related mortality, worldwide. With the use of recently developed anti-tumor agents, the prognoses of patients with unresectable gastric cancer are improving. However, the development of an aggressive treatment strategy for older patients (OPs) remains under debate due to concerns regarding treatment feasibility or patient frailty. We aimed to elucidate whether aggressive chemotherapy has survival benefits for OPs with advanced gastric cancer. METHODS: We analyzed consecutive patients diagnosed with inoperable advanced gastric cancer across seven hospitals from August 2007 to July 2015. We defined OPs as patients aged 75 years or older and compared their survival rates with those of non-older patients (NPs). RESULTS: A total of 256 OPs and 425 NPs were enrolled. Of the OPs, 152 patients received chemotherapy and 104 patients received best supportive care (BSC). In contrast, among the NPs, 375 patients received chemotherapy and 50 patients received BSC. There was no significant difference of the median survival time between OPs and NPs in the response to BSC (61 vs 43 days) or chemotherapy (312 vs 348 days). Combination chemotherapy significantly improved survival compared to monotherapy in both OPs and NPs groups (382 vs 253 days in OPs, 381 vs 209 days in NPs). Good performance status, combination therapy, and male, but not age, were significant independent prognostic factors. CONCLUSION: When the performance status of a gastric cancer patient is good, active chemotherapy may improve survival, regardless of age.
BACKGROUND:Gastric cancer is one of the leading causes of malignant disease-related mortality, worldwide. With the use of recently developed anti-tumor agents, the prognoses of patients with unresectable gastric cancer are improving. However, the development of an aggressive treatment strategy for older patients (OPs) remains under debate due to concerns regarding treatment feasibility or patient frailty. We aimed to elucidate whether aggressive chemotherapy has survival benefits for OPs with advanced gastric cancer. METHODS: We analyzed consecutive patients diagnosed with inoperable advanced gastric cancer across seven hospitals from August 2007 to July 2015. We defined OPs as patients aged 75 years or older and compared their survival rates with those of non-older patients (NPs). RESULTS: A total of 256 OPs and 425 NPs were enrolled. Of the OPs, 152 patients received chemotherapy and 104 patients received best supportive care (BSC). In contrast, among the NPs, 375 patients received chemotherapy and 50 patients received BSC. There was no significant difference of the median survival time between OPs and NPs in the response to BSC (61 vs 43 days) or chemotherapy (312 vs 348 days). Combination chemotherapy significantly improved survival compared to monotherapy in both OPs and NPs groups (382 vs 253 days in OPs, 381 vs 209 days in NPs). Good performance status, combination therapy, and male, but not age, were significant independent prognostic factors. CONCLUSION: When the performance status of a gastric cancerpatient is good, active chemotherapy may improve survival, regardless of age.
Entities:
Keywords:
Best supportive care; Chemotherapy; Gastric cancer; Older patients
Authors: Seung Tae Kim; Kyong Hwa Park; Sang Cheul Oh; Jae Hong Seo; Sang Won Shin; Jun Suk Kim; Yeul Hong Kim Journal: Asia Pac J Clin Oncol Date: 2012-03-12 Impact factor: 2.601
Authors: Paola Bertuccio; Liliane Chatenoud; Fabio Levi; Delphine Praud; Jacques Ferlay; Eva Negri; Matteo Malvezzi; Carlo La Vecchia Journal: Int J Cancer Date: 2009-08-01 Impact factor: 7.396
Authors: Kohei Shitara; Toshihiko Doi; Hisashi Hosaka; Peter Thuss-Patience; Armando Santoro; Federico Longo; Ozgur Ozyilkan; Irfan Cicin; David Park; Aziz Zaanan; Carles Pericay; Mustafa Özgüroğlu; Maria Alsina; Lukas Makris; Karim A Benhadji; David H Ilson Journal: Gastric Cancer Date: 2022-01-08 Impact factor: 7.701